Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil
The FDA approved gabapentin enacarbil in 2011 as the first non-dopaminergic agent for the treatment of restless legs syndrome (RLS) symptoms. Although gabapentin enacarbil is a pro-drug of gabapentin, its pharmacokinetics differ. Absorption of gabapentin enacarbil is more predictable, and inter-pati...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2012-04-01
|
| Series: | Journal of Central Nervous System Disease |
| Online Access: | https://doi.org/10.4137/JCNSD.S9107 |